Market overview
The global pharmaceutical omega-3 API market is worth USD 546 mn in 2026 and is forecast to reach USD 933 mn by 2036, growing at a 5.5% CAGR. United States is the largest country market and EPA ethyl ester is the largest by product segment.
| Scope | Highly purified EPA and DHA omega-3 active ingredients, in ethyl ester, triglyceride and free fatty acid forms, sold to makers of prescription omega-3 drugs and clinical lipid emulsions. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 520 mn |
| Value 2026 | USD 546 mn |
| Value 2036 | USD 933 mn |
| CAGR 2026-2036 | 5.5% |
| Volume 2026 | 836 tonnes |
| Volume 2036 | 1,358 tonnes |
| Average price 2026 | USD 653,200 per tonne |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Pharmaceutical Omega-3 API market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 546 mn |
| 2027 | USD 576 mn |
| 2028 | USD 608 mn |
| 2029 | USD 641 mn |
| 2030 | USD 676 mn |
| 2031 | USD 714 mn |
| 2032 | USD 753 mn |
| 2033 | USD 794 mn |
| 2034 | USD 838 mn |
| 2035 | USD 884 mn |
| 2036 | USD 933 mn |
Pharmaceutical Omega-3 API market segmentation
By product
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| EPA ethyl ester | 36.0% | 42.0% | USD 197 mn | 7.1% |
| EPA plus DHA ethyl ester | 34.0% | 27.2% | USD 186 mn | 3.2% |
| Triglyceride and free acid forms | 18.0% | 19.1% | USD 98 mn | 6.2% |
| DHA-only grades | 12.0% | 11.6% | USD 66 mn | 5.2% |
By end use
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Prescription omega-3 drugs | 72.0% | 69.7% | USD 393 mn | 5.2% |
| Parenteral lipid emulsions | 18.0% | 19.1% | USD 98 mn | 6.2% |
| Clinical nutrition and other | 10.0% | 11.1% | USD 55 mn | 6.7% |
By source
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Fish oil | 68.0% | 62.0% | USD 371 mn | 4.5% |
| Krill oil | 10.0% | 9.0% | USD 55 mn | 4.4% |
| Algal oil | 14.0% | 20.0% | USD 76 mn | 9.3% |
| Other marine and synthetic | 8.0% | 9.0% | USD 44 mn | 6.8% |
By concentration
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Low concentration grades | 12.0% | 10.0% | USD 66 mn | 3.6% |
| Mid concentration grades | 30.0% | 28.0% | USD 164 mn | 4.8% |
| High concentration grades | 38.0% | 38.0% | USD 207 mn | 5.5% |
| Ultra-high purity grades | 20.0% | 24.0% | USD 109 mn | 7.4% |
By route
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Oral capsule grades | 58.0% | 54.0% | USD 317 mn | 4.8% |
| Intravenous emulsion grades | 24.0% | 26.0% | USD 131 mn | 6.3% |
| Enteral and pediatric | 18.0% | 20.0% | USD 98 mn | 6.6% |
Top 25 countries for pharmaceutical omega-3 API by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 85.0% of 2026 revenue and the 25 countries below together hold 95.5%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 218 mn | 40.0% | USD 357 mn | 5.0% |
| 2 | Japan | USD 49 mn | 9.0% | USD 73 mn | 4.0% |
| 3 | China | USD 44 mn | 8.0% | USD 95 mn | 8.1% |
| 4 | Germany | USD 27 mn | 5.0% | USD 45 mn | 5.1% |
| 5 | India | USD 27 mn | 5.0% | USD 59 mn | 8.0% |
| 6 | South Korea | USD 22 mn | 4.0% | USD 39 mn | 6.0% |
| 7 | Canada | USD 22 mn | 4.0% | USD 35 mn | 5.0% |
| 8 | Italy | USD 22 mn | 4.0% | USD 35 mn | 5.0% |
| 9 | France | USD 16 mn | 3.0% | USD 25 mn | 4.4% |
| 10 | Spain | USD 16 mn | 3.0% | USD 27 mn | 5.1% |
| 11 | Norway | USD 13 mn | 2.3% | USD 21 mn | 4.8% |
| 12 | Netherlands | USD 7.6 mn | 1.4% | USD 12 mn | 4.9% |
| 13 | Switzerland | USD 5.6 mn | 1.0% | USD 9.1 mn | 5.0% |
| 14 | Australia | USD 4.5 mn | 0.8% | USD 7.3 mn | 4.8% |
| 15 | Denmark | USD 3.8 mn | 0.7% | USD 6.2 mn | 4.9% |
| 16 | United Kingdom | USD 3.3 mn | 0.6% | USD 5.3 mn | 4.8% |
| 17 | Taiwan | USD 3.0 mn | 0.5% | USD 4.8 mn | 4.9% |
| 18 | Brazil | USD 2.7 mn | 0.5% | USD 6.2 mn | 8.7% |
| 19 | Chile | USD 2.5 mn | 0.5% | USD 4.5 mn | 6.2% |
| 20 | Peru | USD 2.3 mn | 0.4% | USD 5.2 mn | 8.6% |
| 21 | Israel | USD 2.1 mn | 0.4% | USD 4.8 mn | 8.6% |
| 22 | Poland | USD 2.0 mn | 0.4% | USD 4.6 mn | 8.8% |
| 23 | Mexico | USD 1.9 mn | 0.3% | USD 4.3 mn | 8.7% |
| 24 | Belgium | USD 1.8 mn | 0.3% | USD 2.8 mn | 4.8% |
| 25 | Turkey | USD 1.7 mn | 0.3% | USD 3.8 mn | 8.5% |
| Rest of world | USD 25 mn | 4.5% | USD 40 mn | 5.1% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- BASF
- KD Pharma
- Croda
- DSM-Firmenich
Group 2: Regional and specialist players
- Nippon Suisan Kaisha
- Epax
- Chemport
- Polaris
- Maruha Nichiro
Group 3: Emerging and niche players
- Solutex
- Golden Omega
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the pharmaceutical omega-3 API market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 5.5% is calculated from the resulting values.
The market is divided by product, by end use, by source, by concentration, by route. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the pharmaceutical omega-3 API market?
The global pharmaceutical omega-3 API market is estimated at USD 520 mn in 2025 and USD 546 mn in 2026.
How fast will the pharmaceutical omega-3 API market grow?
It is forecast to reach USD 933 mn by 2036, a compound annual growth rate of 5.5% from 2026, an increase of USD 387 mn.
Which country is the largest market for pharmaceutical omega-3 API?
United States is the largest market by revenue at USD 218 mn in 2026, 40.0% of the global total. The three largest countries together hold 57.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 8.1% a year from 2026 to 2036.
Which pharmaceutical omega-3 API segment is largest?
In the by product split, EPA ethyl ester is the largest segment with 36.0% of 2026 revenue.
Who are the leading pharmaceutical omega-3 API companies?
Global leaders include BASF, KD Pharma, Croda, DSM-Firmenich.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Reproductive Toxicity StudiesUSD 549 mn · 5.3% CAGR
- Bone Densitometer DevicesUSD 543 mn · 4.8% CAGR
- Continuous Flow BioreactorsUSD 549 mn · 11.0% CAGR
- Shelf-Stable Clinical MealUSD 551 mn · 6.5% CAGR
- Widefield Imaging SystemsUSD 551 mn · 6.5% CAGR
- Wound Irrigation SystemsUSD 551 mn · 5.8% CAGR
- Cancer Survivorship NutritionUSD 554 mn · 6.5% CAGR
- Micro Balloon CatheterUSD 554 mn · 6.2% CAGR